Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Y. Sawara, M. Itabashi, C. Kojima, H. Tabata, D. Kamei, K. Kawanishi, T. Moriyama, H. Sugiura, M. Tsukada, T. Takei, T. Ogawa, T. Yoshida, J. Arai, K. Uchida, K. Tsuchiya, K. Nitta

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

Original languageEnglish (US)
Pages (from-to)69-72
Number of pages4
JournalClinical Nephrology
Volume72
Issue number1
StatePublished - 2009

Fingerprint

Lipoid Nephrosis
Therapeutic Uses
Recurrence
Therapeutics
B-Lymphocytes
Physicians
Kidney
Rituximab

Keywords

  • Minimal change nephritic syndrome
  • Relapse
  • Remission
  • Rituximab

ASJC Scopus subject areas

  • Nephrology

Cite this

Sawara, Y., Itabashi, M., Kojima, C., Tabata, H., Kamei, D., Kawanishi, K., ... Nitta, K. (2009). Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clinical Nephrology, 72(1), 69-72.

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. / Sawara, Y.; Itabashi, M.; Kojima, C.; Tabata, H.; Kamei, D.; Kawanishi, K.; Moriyama, T.; Sugiura, H.; Tsukada, M.; Takei, T.; Ogawa, T.; Yoshida, T.; Arai, J.; Uchida, K.; Tsuchiya, K.; Nitta, K.

In: Clinical Nephrology, Vol. 72, No. 1, 2009, p. 69-72.

Research output: Contribution to journalArticle

Sawara, Y, Itabashi, M, Kojima, C, Tabata, H, Kamei, D, Kawanishi, K, Moriyama, T, Sugiura, H, Tsukada, M, Takei, T, Ogawa, T, Yoshida, T, Arai, J, Uchida, K, Tsuchiya, K & Nitta, K 2009, 'Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome', Clinical Nephrology, vol. 72, no. 1, pp. 69-72.
Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clinical Nephrology. 2009;72(1):69-72.
Sawara, Y. ; Itabashi, M. ; Kojima, C. ; Tabata, H. ; Kamei, D. ; Kawanishi, K. ; Moriyama, T. ; Sugiura, H. ; Tsukada, M. ; Takei, T. ; Ogawa, T. ; Yoshida, T. ; Arai, J. ; Uchida, K. ; Tsuchiya, K. ; Nitta, K. / Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. In: Clinical Nephrology. 2009 ; Vol. 72, No. 1. pp. 69-72.
@article{d4bdead268ea4dd0885d65c17efb9fc0,
title = "Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome",
abstract = "Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.",
keywords = "Minimal change nephritic syndrome, Relapse, Remission, Rituximab",
author = "Y. Sawara and M. Itabashi and C. Kojima and H. Tabata and D. Kamei and K. Kawanishi and T. Moriyama and H. Sugiura and M. Tsukada and T. Takei and T. Ogawa and T. Yoshida and J. Arai and K. Uchida and K. Tsuchiya and K. Nitta",
year = "2009",
language = "English (US)",
volume = "72",
pages = "69--72",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "1",

}

TY - JOUR

T1 - Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

AU - Sawara, Y.

AU - Itabashi, M.

AU - Kojima, C.

AU - Tabata, H.

AU - Kamei, D.

AU - Kawanishi, K.

AU - Moriyama, T.

AU - Sugiura, H.

AU - Tsukada, M.

AU - Takei, T.

AU - Ogawa, T.

AU - Yoshida, T.

AU - Arai, J.

AU - Uchida, K.

AU - Tsuchiya, K.

AU - Nitta, K.

PY - 2009

Y1 - 2009

N2 - Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

AB - Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

KW - Minimal change nephritic syndrome

KW - Relapse

KW - Remission

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=70349239452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349239452&partnerID=8YFLogxK

M3 - Article

C2 - 19640390

AN - SCOPUS:70349239452

VL - 72

SP - 69

EP - 72

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 1

ER -